



ResAppDx goes live with Doctors on Demand in Australia

Brisbane, Australia, 24 January 2022 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that its ResAppDx acute respiratory diagnostic test has been successfully implemented in Doctors on Demand's online telehealth platform in Australia and is now live on their platform.

Launched in 2015, Doctors on Demand offers both direct-to-consumer (B2C) and business-to-business (B2B) offerings for virtual primary care supported by over 4,000 pharmacies for prescription fulfilment. Doctors on Demand's B2B customers include Flight Centre, Allianz Partners and one of the world's largest mining companies.

Kirsty Garrett, CEO of Doctors on Demand said: *"ResAppDx will help us to revolutionise the telehealth experience of our patients and clinicians by providing instant, diagnostic insights that previously would have required an in-clinic physical examination of the patient. ResAppDx will help our clinicians to appropriately diagnose more patients as part of their video telehealth consultation and importantly identify those patients who do need to be referred for urgent clinical review. We're really excited about the potential of this technology, and we are pleased to launch ResAppDx for the benefit of our patients wherever they are in Australia, whether that's at a remote mine site in the Pilbara or student accommodation in Sydney. We've already had a positive response to this innovation from our B2B clients."*

CEO and Managing Director of ResApp Health, Dr Tony Keating added: *"We are excited to now have ResAppDx live on Doctor on Demand's platform, one of Australia's leading telehealth providers. Our partnership with Doctors on Demand will significantly grow our real-world evidence for ResAppDx in a telehealth setting, providing critical health economic data to support future reimbursement submissions in Australia and elsewhere. We're thankful to Kirsty and her team for their innovation and support through this implementation program and we look forward to hearing how ResAppDx supports Doctors on Demand's patients and clinicians."*

For details on ResApp's agreement with Doctors on Demand refer to ResApp's ASX announcement on 5 July 2021.

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T +61 7 3724 0035 E info@resapphealth.com.au W www.resapphealth.com.au



SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.